Consensus Scholar Rock Holding Corporation

Stocks

SRRK

US80706P1030

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 22/08/2026 HKT			5-day change	1st Jan Change
56.50 ^USD	+2.26%		+7.58%	+28.26%

08-22	Scholar Rock's Global Regulatory Path Further De-Risked, Wedbush Says	MT
08-22	Wedbush Adjusts Scholar Rock Price Target to $64 From $58, Maintains Outperform Rating	MT

Evolution of the Average Target: Scholar Rock Holding Corporation

Evolution of the Target Price: Scholar Rock Holding Corporation

Changes in Analyst Recommendations: Scholar Rock Holding Corporation

801d17c471c16ee62b4c5109.l3IeE1YWGRwAK7Ydok140joOkyAbTfvkgd0q2cUxlyY.7jN5PjpfVnhaU_JJ5C8osGM9o0d6HrmCz5obrKFL5XPCOnpBCSNab2Nbhg~4809bca3520f07f8eaac7a0ce0df3c9a

Analysts' recommendations: Scholar Rock Holding Corporation

08-22	Wedbush Adjusts Scholar Rock Price Target to $64 From $58, Maintains Outperform Rating	MT
04-21	Canaccord Genuity Initiates Scholar Rock at Buy With $62 Price Target	MT
03-31	Wedbush Adjusts Price Target on Scholar Rock Holding to $58 From $56, Maintains Outperform Rating	MT
03-04	Truist Raises Price Target on Scholar Rock Holding to $55 From $44, Keeps Buy Rating	MT
03-03	Wedbush Adjusts Price Target on Scholar Rock to $56 From $50, Maintains Outperform Rating	MT
01-07	UBS Initiates Scholar Rock Holding at Buy With $60 Price Target	MT
11-15	Wedbush Adjusts Pt on Scholar Rock Holding to $50 From $43, Maintains Outperform Rating	MT
23/09/25	HC Wainwright Adjusts Price Target on Scholar Rock Holding to $44 From $50, Maintains Buy Rating	MT
23/09/25	Scholar Rock's Apitegromab Approval Still Likely Despite Delay, Wedbush Says	MT
17/09/25	Barclays Initiates Scholar Rock at Overweight With $45 Price Target	MT
15/09/25	Leerink Partners Initiates Scholar Rock at Outperform With $51 Price Target	MT
06/08/25	Biopharma Scholar Rock Q2 net loss widens, no revenue	RE
18/07/25	Truist Raises Price Target on Scholar Rock Holding to $54 From $45, Keeps Buy Rating	MT
17/07/25	Cantor Fitzgerald Initiates Coverage on Scholar Rock With Overweight Rating	MT
28/02/25	Wedbush Adjusts Scholar Rock Price Target to $50 From $47, Maintains Outperform Rating	MT
25/11/24	Wedbush Raises Price Target on Scholar Rock to $47 From $40, Maintains Outperform Rating	MT
25/11/24	Truist Securities Adjusts Price Target on Scholar Rock to $45 From $36, Maintains Buy Rating	MT
12/11/24	Wedbush Raises Price Target on Scholar Rock to $40 From $37, Maintains Outperform Rating	MT
08/10/24	Scholar Rock's Spinal Muscular Atrophy Drug Plans for Children Under 2 Could Broaden Patient Group, Truist Says	MT
07/10/24	Scholar Rock's Phase 3 Apitegromab Trial in Spinal Muscular Atrophy Meets Primary Endpoint	MT
07/10/24	Wedbush Raises Price Target on Scholar Rock Holding to $27 From $25, Keeps Outperform Rating	MT
07/10/24	Truist Raises Price Target on Scholar Rock Holding to $36 From $20, Keeps Buy Rating	MT
27/09/24	Wedbush Raises Price Target on Scholar Rock to $25 From $23, Keeps Outperform Rating	MT
13/06/24	BMO Capital Raises Price Target on Scholar Rock to $31 From $29, Maintains Outperform Rating	MT
28/03/24	Raymond James Initiates Scholar Rock With Strong Buy Rating, $30 Price Target	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Objective/dr gap
SCHOLAR ROCK HOLDING CORPORATION		+7.52%
WUXI APPTEC CO., LTD.		+12.08%
ARGENX SE	-	+3.64%
BIONTECH SE		+4.24%
INSMED INCORPORATED		+59.06%
WUXI BIOLOGICS (CAYMAN) INC.		-6.88%
GENMAB A/S		+12.06%
PHARMAESSENTIA CORPORATION		-6.27%
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.		+13.86%
EXELIXIS, INC.		-2%
Average		+9.73%
Weighted average by Cap.		+10.30%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

56.50USD

Average target price

60.75USD

Spread / Average Target

+7.52%

High Price Target

76.00USD

Spread / Highest target

+34.51%

Low Price Target

48.00USD

Spread / Lowest Target

-15.04%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Wedbush
Canaccord Genuity
Truist Securities
UBS
HC Wainwright
Barclays
Leerink Partners
Cantor Fitzgerald
BMO Capital
Raymond James
Jefferies & Co.
Piper Sandler
JPMorgan Chase